C08DB01 - Diltiazem |
Probably porphyrinogenic |
PRP |
Rationale
Substrate for several CYPs, including 3A4. Potent mechanism-based CYP3A4 inhibitor.
Chemical description
Benzodiazepine dervative with calcium antagonistic action, metabolized to desmetyl and desacetyl diltiazem. Substrate of CYPs 2C8, 2C9, 2D6, 3A4, 3A5, 3A7. Inhibitor of 2C8, 2C9, 2D6. Potent mechanism-based inhibitor of 3A4.
Personal communication
Andersson, patient report (n=3): tolerated.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
References
| # | Citation details | PubMed ID |
|---|---|---|
| 1. | Porphyrias.
James MF, Hift RJ. Br J Anaesth. 2000 Jul; 85(1):143-53.
|
10928003 |
| 2. | Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases.
Kauppinen R, Mustajoki P. Medicine (Baltimore). 1992 Jan; 71(1):1-13.
|
1549056 |
| Porphyria Drug Lists | ||
| 3. | French List
Centre Français des Porphyries
|
|
| 4. | EPI List
European Porphyria Initiative No longer maintained
|
|
| 5. | South African List
Porphyria South Africa No longer maintained
|
|
Tradenames